Company intelligence / Profile preview
Aimil Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Aimil Pharmaceuticals is a leading Indian company specializing in scientifically validated Ayurvedic medicines and natural healthcare products. The company has developed several market-leading brands for chronic and lifestyle diseases such as diabetes (BGR–34), chronic kidney disease (Neeri KFT), leucoderma/vitiligo (Lukoskin), and others. Many of its formulations are developed in collaboration with top Indian research institutions like CSIR and DRDO. Its products are available globally across more than thirty countries, with strong clinical validation for key brands such as BGR–34 and Lukoskin.
- Therapeutic areas
- Infectious DiseasesDermatologyGastroenterologyEndocrinologyHematologyNephrology
- Modalities
- Herbal medicineAyurvedic formulationSmall molecule (plant-derived)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Aimil Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aimil Pharmaceuticals.